

CURRICULUM VITAE

Name: Luciano Jose Megale Costa, M.D., Ph.D.

Office: Hematology/Oncology Division
Medical University of South Carolina
96 Jonathan Lucas Street - 903 CSB
Mail Stop Code 6350
Charleston, SC 29425
(843) 792-5283
costalj@musc.edu

EDUCATION:

Medical Education: Universidade de Sao Paulo
Sao Paulo, Brazil
M.D.
1993 – 1998

Universidade de Sao Paulo
Sao Paulo, Brazil
Ph.D.
2003 – 2006
**Thesis: "Cell Signaling and Translation Initiation Complex
Modulation as Strategy in the Treatment of Renal Cell
Carcinoma"

Postgraduate Training: Universidade de Sao Paulo
Sao Paulo, Brazil
Residency – Internal Medicine
02/01/1999 – 01/31/2003

University of Colorado Health Sciences Center
Fellowship – Hematology and Medical Oncology
10/01/2003 – 11/08/2006

Mayo Clinic, Rochester, MN
Fellowship – Blood and Marrow Transplantation
11/09/2006 – 11/08/2007

Additional Training: AACR Workshop in Cancer Research
Aspen – Colorado
06/30/2005 – 07/06/2005

ASBMT Research Training Course
Park City, UT
07/30/2008 – 08/04/2008

FACULTY APPOINTMENTS:

Assistant Professor
Hematology and Medical Oncology
Medical University of South Carolina
Charleston, South Carolina
2008 –

LICENSURE:

South Carolina (Active)
Michigan (Inactive)
Minnesota (Inactive)
Colorado (Inactive)

ECFMG certificate

EXPERIENCE/SERVICE:

Permanent Member
Hollings Cancer Center Protocol Review Committee
Medical University of South Carolina
2009-

Member
Hematology and Medical Oncology Fellowship Committee
Medical University of South Carolina
2009 –

Member
University of Colorado Cancer Center Protocol Review
And Monitoring Committee
2005 – 2006

Chief Fellow
Hematology/Medical Oncology Fellowship Committee
University of Colorado
2005 – 2006

Lecturer
Hematologic Pathology
Sao Paulo University Medical School
Sao Paulo, Brazil
2003

Lecturer
Hematology
ABC Foundation School of Medicine
Sao Paulo, Brazil
2003

PROFESSIONAL MEMERSHIPS/ACTIVITIES:

Member, American Society of Hematology

Member, American Society of Clinical Oncology

Member, American Society for Blood and Marrow Transplantation

Member, American Association of Cancer Research

RESEARCH ACTIVITIES:

A. Non-Clinical Trial Grants:

1. Travel Grant: American Society of Hematology; 2007
2. Seed Grant: University of Colorado Cancer Center; 2004; \$10,000 Project "EGFR in Renal Cell Carcinoma"
3. Post-Graduate Student Grant: National Research Council; 2003; R\$13,000/year
4. Student Investigator Award: Brazilian National Research Council; 1996 – 1998
R\$3100/year

B. Clinical Trials:

NCT00849147 A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies. Site PI MUSC Charleston, SC. \$83,444

NCT00481871 A Phase 1/2a Open-Label Study of Sequential Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With

Relapsed or Refractory Lymphoproliferative Malignancies. Site PI MUSC Charleston, SC. \$108,995

NCT00773747 An International, Multi-Center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma. Site PI MUSC Charleston, SC\$152,943

NCT00366145 A Phase III, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Prochymal (ExVivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid-refractory Acute GVHD. Site co-investigator at Mayo Clinic, Rochester, MN.

NCT00353301 Phase II single arm clinical trial to evaluate the efficacy and safety of the combination of Tarceva® (erlotinib hydrochloride) and Rapamune® (sirolimus) in the treatment of metastatic renal cell carcinoma (accruing). Co-investigator in this PI initiated trial at University of Colorado Cancer Center.

NCT00244764 A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects With Locally Recurrent of Metastatic Clear-Cell Carcinoma Site co-investigator at University of Colorado Cancer Center.

NCT00083889 A Phase III, Randomized Study of SU011248 Versus Interferon-Alpha As First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma. Site co-investigator at University of Colorado Cancer Center.

NCT00111020 Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients with Advanced Renal Cell Carcinoma. Site co-investigator at University of Colorado Cancer Center.

NCT00117637 A Randomized, Open-Label, Multi-Center Phase II Study of First Line Treatment with BAY 43-9006 (Sorafenib) Versus Standard Treatment with Interferon Alpha-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma. Site co-investigator at University of Colorado Cancer Center.

NCT00130897 A SU011248 Treatment Protocol for Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation in Other SU011248 Protocols and May Derive Benefit from Treatment with SU011248 Site co-investigator at University of Colorado Cancer Center.

NCT00073307 A Phase III Randomized Study of BAY 43-9006 in Patients with Unresectable and/or Metastatic Renal Cell Cancer. Site co-investigator at University of Colorado Cancer Center.

NCT00081614 A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination with Avastin (Bevacizumab) versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma. Site co-investigator at University of Colorado Cancer Center.

PUBLICATIONS:

A. Articles in Peer – Reviewed Journals:

Costa L.J. Impact of allogeneic hematopoietic stem cell transplantation in the outcome of Ph positive acute lymphoblastic leukemia treated with an imatinib containing regimen. Br J Haematol 146: 576-577, 2009.

Adams B.R., Miller A.N., **Costa L.J.** Self limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 2009 (in press).

Costa L.J., Kumar S., Dispenzieri A., Hayman S.E., Buadi F.K., Dingli D., Litzow M.R., Gertz M.A., Lacy M.Q. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia Lymphoma, 50:781-7, 2009.

Costa L.J., Micallef I.N, Inwards D.J, Johnston P.B., Porrata L.F., Litzow M.R., Ansell S.M. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed DLBCL. Br J Haematol 143:268-273, 2008.

Costa L.J., Rodriguez V., Porrata L.F., Lacy M.Q., Elliot M.A., Gertz M.A., Gastineau D.A., Litzow M.R. Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancy. Bone Marrow Transplant 42:497-498, 2008.

Costa L.J., Feldman A.L., Micallef I.N, Inwards D.J, Johnston P.B., Ansell S.M. Germinal center B cell and non-germinal center B cell-like DLBCL have similar outcome following autologous HSC transplantation. Br J Haematol 142:404-412, 2008.

Costa L.J., Micallef I.N, Inwards D.J, Johnston P.B., Porrata L.F., Ansell S.M. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant 41:715-20, 2008.

Costa L.J., Drabkin H. Renal Cell Carcinoma: New developments in molecular biology and potential for targeted therapies. Oncologist 12:1404-15, 2007.

Ballonoff A., Kavanagh B., Nash R., Drabkin H., Trotter J., **Costa L.**, Rabinovitch R.. Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: Statistical analysis of all published cases and literature review. Acta Oncol 47:962-970, 2007.

Costa L.J., Gemmill R.M., Drabkin H.A. Upstream signaling inhibition enhances the rapamycin effect on growth of Kidney Cancer Cells. Urology 69:596-602, 2007.

Costa L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. *Cancer Treat Rev* 33:78-84, 2007.

Xavier A.C., Marshall C., La Rosa FG, **Costa L.J.**, Drabkin H., Crawford E.D. Woman with a papillary pulmonary lesion and a complex renal cyst. *Oncology (Williston Park)* 20:1437-1443, 2006

Gemmill R.M., Zhou M., **Costa L.J.**, Korch C., Bukowski R.M., Drabkin H. Synergistic Growth Inhibition by Iressa and Rapamycin Is Modulated by VHL Mutations in Renal Cell Carcinoma. *Br J Cancer* 92:2266-2277, 2005

Xavier A.C., Siqueira S.A., **Costa L.J.**, Mauad T., Saldiva P.H.. Missed diagnosis in hematological patients - an autopsy study. *Virchows Arch.* 446:225-231, 2005

Samano E..S, Ribeiro L.M., Campos A.S., Lewin .F, Filho E.S., Goldenstein P.T., **Costa L.J.**, del Giglio A. Use of complementary and alternative medicine by Brazilian oncologists. *Eur J Cancer Care (Engl)*14:143-148, 2005.

del Giglio A., **Costa L.J.** The quality of randomized controlled trials may be better than assumed. *BMJ* 328:24-25, 2004

Costa L.J., Xavier A.C., del Giglio A.. "Negative" results in cancer clinical trials – equivalence or poor accrual?. *Control Clin Trials* 25:525-533, 2004

Fonseca F.L., SantAna A.V., Bendit I., Arias V., **Costa L.J.**, Pinhal A.A., del Gilgio A. Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. *Breast Cancer Res*, 7:R28-R32, 2004

Megale **Costa L.J.**, Soares H.P., Gaspar H.A., Trujillo L.G., Santi P.X., Pereira R.S., de Santana T.L., Pinto F.N., del Giglio A. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. *Am J Clin Oncol.*27:304-306, 2004

Costa L.J., Gallafrio C.T., Franca F.O., del Giglio A. Simultaneous occurrence of Hodgkin disease and tuberculosis: report of three cases. *South Med J.* 97:696-698, 2004

Costa L.J., Varella P.C., Del Giglio A. White coat effect in breast cancer patients undergoing chemotherapy. *Eur J Cancer Care* 12:372-373, 2003

Costa L.J.M., Varella P.C.S., Giglio A. Weight changes during chemotherapy for breast cancer. *São Paulo Med J* 120:113-117, 2002

Costa L.J.M., Giglio A. Manejo da leucemia mielóide crônica (Management of chronic myelocytic leukemia). *Rev Soc Bras Oncol Clin* 1:45-52, 1999

Giglio A., **Costa L.J.M.**, Pinczowski H., Varella P.C.S., Luzzi J.R., Neves P. Mota

A., Boente P., Sampaio C. Pilot study of the combination of Melphalan, Carboplatin and Etoposide as a conditioning regimen for relapsed lymphoma patients. *Acta Haematol* 102:56-58, 1999

Costa L.J.M., Varella P.C.S., Auro del Giglio A Utilização de anticorpos monoclonais em oncologia (*The role of monoclonal antibodies in oncology*). *Rev Soc Bras Cancerol* 2:32-39, 1998

Costa L.J.M.; Varella P.C.S.; Arias V.; Auro del Giglio. Síndrome de Sjögren e Linfoma Não Hodgkin: Apresentação de um caso e revisão da literatura. (*Sjögren syndrome and non-Hodgkin lymphoma: report of a case and review of the literature*). *Bol. Hematol* 9:6-9, 1998

Costa L.J.M.; Varella P.C.S.; Auro del Giglio. Câncer de Primário desconhecido: uma abordagem para o clínico (*Cancer of unknown primary site: an approach for internists*) *Rev Bras Clin Terap* 24:77-83, 1998

del Giglio A.; Pinczowski H.; Feher O.; Varella P.C.S.; Dimambro I.A.; Luzzi J.R.; Neves P.A.; **Costa L.J.M.** Quimioterapia de altas doses e transplante autólogo de medua óssea no tratamento de câncer de mama: Revisão da literatura e experiência preliminar do grupo de quimioterapia de altas doses do Hospital Samaritano (*High dose chemotherapy and autologous bone marrow transplantation on the treatment of breast cancer: review of the literature and preliminar results from the Samaritan Hospital high dose chemotherapy group*). *Rev Bras Mastol* 7:75-82, 1997

Blunk V, Bueno L.M., Nicoletti A.G.B, Gasparini F.F, Guedes K.F., Pico K.A., **Costa L.J.M.**, Kanda J.L., Nívola A.C., Giglio A., Zatta S.M., Gertner S.K. Quimioterapia em tumores de cabeça e pescoço (Chemotherapy for head and neck cancer). *Arq Med ABC* 1:2-6, 1997

Chaib E.; Bertevello P.; Pinto F.C.G.; Ferreira C.E.H.; Nagahama C.I.; Cahali R.B.; Beer I.; Perini M.V.; Xavier A.C.G.; **Costa L.J.M.** Principais variações do sistema biliar extra-hepático e sua aplicação na técnica de transplante de fígado chamada "split-liver" (*Study of the hepatic duct system for application of the split-liver transplantation technique*); *Rev Hosp Clin Fac Med S Paulo* 50(6):311-313, 1995

B. Abstracts:

Alexander E., **Costa L.J.**, Taylor M., Hogan K., Fouts T., Schaub C., Stuart R.K. Cost-Effective Use of Plerixafor for Hematopoietic Stem Cells Mobilization: Development and Validation of a Decision-Making Algorithm. American Society of Hematology 51th annual meeting, 2009

Shabbir M., **Costa L.J.**, Hogan K., Fouts T., Kramer C., Maxwell C., Schaub C., Stuart R.K. Excessive Rate of Late Infections and Treatment Related Mortality Associated with the Use of Alemtuzumab in Reduced Intensity Conditioning for

Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Trial. American Society of Hematology 51th annual meeting, 2009

Costa L.J.M., Sharma G., Gemmill R.M., Drabkin H. The combination of sorafenib and vorinostat causes synergistic growth inhibition in kidney cancer cells. American Society of Clinical Oncology Genitourinary Cancers Symposium abstract 402, 2008.

Costa L.J., Feldman A.L., Micallef I.N, Inwards D.J, Johnston P.B., Ansell S.M. Germinal center B Cell and non-germinal center B cell-like DLBCL have similar clinical features at the time of progression and comparable outcome following autologous HSC transplantation.. American Society of Hematology 49th annual meeting. Blood 110:1901, 2007

Costa L.J., Micallef I.N, Inwards D.J, Johnston P.B., Ansell S.M. A Higher Ratio of Dose to actual weight of conditioning chemotherapy leads to more toxicity without improvement in outcome in autologous HSC transplant for DLBCL. American Society of Hematology 49th annual meeting. Blood 110:3017, 2007

Costa L.J., Rodriguez V., Porrata L.F., Lacy M.Q., Elliott M.A., Tefferi A., Lust J.A., Letendre L., Colgan J.P., Gertz M.A., Gastineau D.A., Litzow M.R. Experience with autologous HSC transplant in therapy-related MDS/AML using cells harvested prior to the development of the secondary malignancy. American Society of Hematology 49th annual meeting. Blood 110:5099, 2007

Costa L.J., Micallef I.N, Inwards D.J, Johnston P.B., Ansell S.M. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous HSC transplantation. American Society of Hematology 49th annual meeting.. Blood 110:1897, 2007

Costa L.J., Kumar S., Dispenzieri A, Hayman SE, Buadi FK, Litzow M.R., Gertz M.A., Lacy M.Q. Allogeneic HSC transplantation for multiple myeloma: A single institution experience.. American Society of Hematology 49th annual meeting. Blood 110:3036, 2007

Flaig T.W., Breaker K., Crighton F., Schultz M., **Costa L.J.**, Kim F., Drabkin H.A. The combination of Tarceva and Rapamune in the treatment of advanced renal cell carcinoma: Interim safety and tolerability assessment. V International Kidney Cancer Symposium, 2007.

Costa L.J., Gonzalez M., Breaker K., Ellis K., Crighton F., Kim F., Drabkin H.A. Sunitinib malate has activity in advanced RCC previously treated with sorafenib. IV International Kidney Cancer Symposium, 2006.

Costa L.J.M., Gemmill R.M., Drabkin H. Preclinical analysis of rapamycin plus EGFR or MEK1/2 inhibitors in renal cell carcinoma (RCC). American Association of Cancer Research annual meeting, 2006.

del Giglio A., Fonseca F.L.A., Santana A., Pinhal M.A.S., Bendit I, **Costa L.J.M.**, Arias V. Microsatellite instability (MSI) and loss of heterozigocidade (LOH) in the peripheral blood mononuclear cells (PBMC) of breast cancer (BC) patients receiving systemic chemotherapy. American Society of Clinical Oncology 40th annual meeting. *J Clin Oncol*, 22(14S):9628, 2004

Tibana Samano E.S., Del Giglio A., Ribeiro L.M., Campos A. S., Lewin F, Valesin Filho E. S., Goldenstein P.T., **Costa L.J.M.** Use of complementary/alternative medicine by Brazilian oncologists. American Society of Clinical Oncology 40th annual meeting. *J Clin Oncol* 22(14S):8196, 2004

Pasqualucci C.A.; **Costa L.J.M.**; Lage S.G. Histometric study of vasa vasorum remodeling in ascending aorta. *Eur Heart Jour*. 19:36 P418, 1998

Costa L.J.M.; Caldini, E.G.; Santarém, J.M.; Pasqualucci, C.A Quantificação de colágeno no miocárdio de ratos de diferentes faixas etárias submetidos a exercício aeróbio e anaeróbio (*Quantification of collagen in mice myocardium after aerobic and anaerobic activity at different ages*). Resumos do IV Simpósio de Iniciação Científica da Universidade de São Paulo, p.237, 1996.

Costa L.J.M.; Pasqualucci C.A. Ruptura de aorta torácica e hipertensão arterial sistêmica: estudo da remodelação vascular dos vasa vasorum (*Rupture of the thoracic aorta and systemic hypertension: study of vasa vasorum remodeling*). Resumos do V Simpósio de Iniciação Científica da Universidade de São Paulo, p.221, 1997.

Del Giglio A, Pinczowski H.; Feher O.; Varella P.C.S.; Dimambro I.A.; Luzzi J.R.; Neves P.A.; **Costa L.J.M.** High dose chemotherapy (HDC) for metastatic breast cancer(MBC). Preliminary experience of Hospital Samaritano de São Paulo (HSSP) high dose chemotherapy group. Proceedings Convenção Latino Americana da European School of Oncology (ESO) 15:A24, 1997

Del Giglio A, Pinczowski H.; Feher O.; Varella P.C.S.; Dimambro I.A.; Luzzi J.R.; Neves P.A.; **Costa L.J.M.** Altas doses de quimioterapia (ADQT) para câncer de mama metastático (CMM): experiência preliminar do grupo de altas doses de quimioterapias do hospital samaritano de São Paulo (HSSP) (*High dose chemotherapy (HDC) for metastatic breast cancer(MBC). Preliminary experience of Hospital Samaritano de São Paulo (HSSP) high dose chemotherapy group*). Resumos IV Congresso Brasileiro de Oncologia Clínica 58, 1997

Pasqualucci C.A.; **Costa L.J.M.** ;Lage S.G. Estudo da remodelação de vasa vasorum na dissecação de aorta ascendente associada à hipertensão arterial sistêmica (*Study of vasa vasorum remodeling in ascending aorta dissection related to high blood pressure*). Resumos da XIII Reunião Anual da Federação das Sociedades de Biologia Experimental, 1998

Costa, L.J.M., Lage S.G., Pasqualucci C.A Associação entre hipertensão arterial

sistêmica e dissecação aguda de aorta: contribuição ao conhecimento fisiopatológico (*Association between high blood pressure and acute aortic dissection: contribution on understanding of the pathophysiology*). Resumos do II Congresso Paulista de Clínica Médica, 1998

Costa L.J.M.; Varella P.C.S.; del Giglio A. Utilização de anticorpos monoclonais no tratamento de linfoma não-Hodgkin-B de baixo grau recidivado (LNH-B) com expressão de CD20: experiência preliminar em 3 casos (*Use of monoclonal antibodies in relapsed low-grade B cell lymphomas with CD 20 expression: preliminary results in three cases*). Resumos do II Congresso Paulista de Clínica Médica, 1998

C. Book Chapters:

Gemmil R.M., **Costa L.J.**, Medeiros B., Drabkin H. Molecular pathogenesis of renal cancer and related treatment aspects. In diseases of the kidney and urinary tract. Schrier R.W. eds. 8th edition, 2005 .

Costa L.J., Kane M. Chemotherapy for head and neck cancer. In ENT secrets. Jafek B.W., Murrow B.W. eds. 3rd edition, 2005.

Costa L.J.M., Giglio A. Marcadores moleculares em oncologia (*Molecular markers in oncology*). In Oncologia Clínica. Brentani M eds., 2003.

Costa L.J.M., Giglio A. Quimioterapia em tumores de cabeça e pescoço (*Chemotherapy for head and neck cancer*). In Manual do residente de cirurgia de cabeça e pescoço. Vergilius J.F. Araújo Filho, Lenine Garcia Brandão, Alberto R. Ferraz eds. São Paulo, Keila & Rosenfeld, 1999.

EDITORIAL AND REVIEW ACTIVITIES:

A. Ad hoc reviewer

Blood
Bone Marrow Transplantation
Contemporary Clinical Trials.
Biologics: Targets and Therapy
World Journal of Urology
Cancer Letters

TEACHING:

A. Courses Taught

University of Colorado School of Medicine. Hematology; 2005 and 2006.

University of Colorado School of Medicine. Oncology; 2006.

Sao Paulo University Medical School. Sao Paulo, Brazil. Hematopathology, 2003.

ABC Foundation School of Medicine. Sao Paulo, Brazil. Hematology, 2003

B. Lectures

MUSC Department of Medicine Grand Rounds. Unfolding non-Hodgkin lymphoma. 2009.

Mayo Clinic blood and marrow transplantation curriculum. High-dose chemotherapy with hematopoietic stem cell support in Germ Cell Tumors. 2007

Mayo Clinic blood and marrow transplantation curriculum. Current status of transplantation for chronic myelogenous leukemia. 2007

Mayo Clinic blood and marrow transplantation curriculum. Veno-occlusive disease. 2007

Mayo Clinic blood and marrow transplantation curriculum. Transplantation in normal karyotype acute myelogenous leukemia. 2007

Mayo Clinic blood and marrow transplantation curriculum. Acute graft-versus-host disease. 2007

University of Colorado, Division of Medical Oncology Grand Rounds. Normal Karyotype AML. What is coming out of the black box? 2006

University of Colorado, Division of Medical Oncology Grand Rounds. Aspects of mTOR biology. Growth, Translation and Cancer Therapy; 2006

University of Colorado Hematological Malignancies Conference. Early Hodgkin lymphoma; 2006

University of Colorado, Division of Medical Oncology. NF-kB in Kidney Cancer; 2005

University of Colorado, Division of Medical Oncology. Marginal zone B cell lymphoma; 2005

University of Colorado, Division of Medical Oncology. Interpreting cancer literature. What do the negative studies really mean? 2004

Pouso Alegre School of Medicine. Introduction to study and practice of oncology. Pouso Alegre, Brazil; 2002.

C. Other

Responsible for the scientific agenda for the weekly hematology meeting.
Medical University of South Carolina, 2008-

Preceptorship in Kidney Cancer. University of Colorado. Cell signaling in kidney cancer; 2005.

USMLE preparatory course- Sao Paulo, Brazil. Immunology, microbiology, pathology and internal medicine, 1999-2002.

COMMUNITY/ VOLUNTEER WORK:

Medical Director, Tri-county cancer survivors, Inc. 2009-

American Society of Hematology / Health Volunteers Overseas – 3 week assignment to Mulago Hospital, Kampala, Uganda. 2008

Lecture to the Leukemia and Lymphoma Society support group; Denver, CO. Waldenström's macroglobulinemia; 2006

Lecture to the University of Colorado Kidney Cancer Support Group. Update on treatment of kidney cancer; 2006.

Lecture to the University of Colorado Kidney Cancer Support Group. Image techniques in kidney cancer; 2005.